{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=86",
    "query": {
      "condition": "Multi Center",
      "page": 86
    },
    "page_size": 10
  },
  "pagination": {
    "page": 86,
    "page_size": 10,
    "total_count": 6600,
    "total_pages": 660,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=87&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=85&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T07:32:21.811Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03644277",
      "title": "A Multi-Center Clinical Trial in Individuals With Spinal Cord Injury",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Cord Injuries"
      ],
      "interventions": [
        {
          "name": "Acute Intermitted Hypoxia",
          "type": "OTHER"
        },
        {
          "name": "Massed Practise",
          "type": "PROCEDURE"
        },
        {
          "name": "Rapael Glove",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Shirley Ryan AbilityLab",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 121,
      "start_date": "2018-07-01",
      "completion_date": "2026-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-24",
      "last_synced_at": "2026-11-09T07:32:21.811Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • East Hanover, New Jersey",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03644277"
    },
    {
      "nct_id": "NCT00033254",
      "title": "Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tumors Metastatic to Brain"
      ],
      "interventions": [
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 332,
      "start_date": "2002-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-10-30",
      "last_synced_at": "2026-11-09T07:32:21.811Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00033254"
    },
    {
      "nct_id": "NCT00813566",
      "title": "Multi-Tracer PET Assessment of Primary Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Tumors",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "[18F]fluoro-2-deoxy-D-glucose (FDG)",
          "type": "DRUG"
        },
        {
          "name": "3'-deoxy-3'-[18F]fluorothymidine (FLT)",
          "type": "DRUG"
        },
        {
          "name": "[15O]-H2O",
          "type": "DRUG"
        },
        {
          "name": "[11C]Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2010-11-12",
      "completion_date": "2015-02-03",
      "has_results": false,
      "last_update_posted_date": "2022-04-27",
      "last_synced_at": "2026-11-09T07:32:21.811Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00813566"
    },
    {
      "nct_id": "NCT05309694",
      "title": "A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "Paragard® T380A Intrauterine Copper Contraceptive with New Inserter",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "CooperSurgical Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 119,
      "start_date": "2022-03-04",
      "completion_date": "2022-12-08",
      "has_results": true,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-11-09T07:32:21.811Z",
      "location_count": 8,
      "location_summary": "Denver, Colorado • South Miami, Florida • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Saginaw",
          "state": "Michigan"
        },
        {
          "city": "Franklin",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05309694"
    },
    {
      "nct_id": "NCT04313400",
      "title": "Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "1.1% w/w AMTX-100 CF-part1",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "1.1% w/w AMTX-100 CF3-part2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amytrx Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2020-03-10",
      "completion_date": "2024-01-02",
      "has_results": true,
      "last_update_posted_date": "2025-05-02",
      "last_synced_at": "2026-11-09T07:32:21.811Z",
      "location_count": 11,
      "location_summary": "Cerritos, California • Encino, California • Long Beach, California + 8 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04313400"
    },
    {
      "nct_id": "NCT07604571",
      "title": "Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced HR+/HER2- Breast Cancer"
      ],
      "interventions": [
        {
          "name": "IEV407",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2026-05-28",
      "completion_date": "2032-06-08",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-09T07:32:21.811Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Kansas City, Kansas • Dallas, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07604571"
    },
    {
      "nct_id": "NCT00369577",
      "title": "Staccato Loxapine in Agitation (Proof of Concept)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Inhaled Placebo",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Loxapine 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Loxapine 10 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexza Pharmaceuticals, Inc.",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 129,
      "start_date": "2006-08",
      "completion_date": "2007-01",
      "has_results": true,
      "last_update_posted_date": "2018-01-02",
      "last_synced_at": "2026-11-09T07:32:21.811Z",
      "location_count": 1,
      "location_summary": "Upland, California",
      "locations": [
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00369577"
    },
    {
      "nct_id": "NCT06147336",
      "title": "A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "V-LAP™ SYSTEM",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Vectorious Medical Technologies Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "88 Years",
        "sex": "ALL",
        "summary": "22 Years to 88 Years"
      },
      "enrollment_count": 10,
      "start_date": "2024-06-11",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2025-05-30",
      "last_synced_at": "2026-11-09T07:32:21.811Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06147336"
    },
    {
      "nct_id": "NCT01308567",
      "title": "Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Cabazitaxel (XRP6258)",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel (XRP6976)",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1168,
      "start_date": "2011-05-05",
      "completion_date": "2018-05",
      "has_results": true,
      "last_update_posted_date": "2019-06-05",
      "last_synced_at": "2026-11-09T07:32:21.811Z",
      "location_count": 32,
      "location_summary": "Muscle Shoals, Alabama • Anaheim, California • Bakersfield, California + 28 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01308567"
    },
    {
      "nct_id": "NCT03808298",
      "title": "Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Balovaptan therapeutic dose Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Balovaptan supra-therapeutic dose Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Active control [moxifloxacin] on Day 2 Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Active control [Moxifloxacin] on Day 15 Treatment D",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Balovaptan Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Balovaptan Treatment D",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Moxifloxacin Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Moxifloxacin Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Moxifloxacin Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Moxifloxacin Treatment D",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin Treatment D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 57,
      "start_date": "2019-02-07",
      "completion_date": "2019-07-13",
      "has_results": true,
      "last_update_posted_date": "2020-07-24",
      "last_synced_at": "2026-11-09T07:32:21.811Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03808298"
    }
  ]
}